These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37577308)

  • 21. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
    Hernandez L; Young M
    J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
    [No Abstract]   [Full Text] [Related]  

  • 22. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
    Watanabe N; Horio Y; Fujiwara Y
    Ann Transl Med; 2022 Dec; 10(23):1283. PubMed ID: 36618815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.
    Petrini I; Giaccone G
    Onco Targets Ther; 2022; 15():1197-1210. PubMed ID: 36246734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
    Waliany S; Wakelee H; Ramchandran K; Das M; Huang J; Myall N; Li C; Pagtama J; Tisch AH; Neal JW
    Clin Lung Cancer; 2022 Sep; 23(6):498-509. PubMed ID: 35753988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
    Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
    Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
    [No Abstract]   [Full Text] [Related]  

  • 29. Mobocertinib (TAK-788): A Targeted Inhibitor of
    Gonzalvez F; Vincent S; Baker TE; Gould AE; Li S; Wardwell SD; Nadworny S; Ning Y; Zhang S; Huang WS; Hu Y; Li F; Greenfield MT; Zech SG; Das B; Narasimhan NI; Clackson T; Dalgarno D; Shakespeare WC; Fitzgerald M; Chouitar J; Griffin RJ; Liu S; Wong KK; Zhu X; Rivera VM
    Cancer Discov; 2021 Jul; 11(7):1672-1687. PubMed ID: 33632773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.
    Boch T; Köhler J; Janning M; Loges S
    Cancer Biol Med; 2022 Dec; 19(11):1543-64. PubMed ID: 36476337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
    Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
    BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
    Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
    Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
    Yang X; Zhao J
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
    Gursoy P; Tatli AM; Erdem D; Goker E; Celik E; Demirci NS; Sakin A; Atci MM; Bayram E; Telli TA; Bilgin B; Bilici A; Akangunduz B; Balli S; Demirkazik A; Selçukbiricik F; Menekse S; Cavdar E; Ozturk A; Bekmez ET; Turhal S; Kilickap S; Yildirim HÇ; Oyan B; Aksoy A; Turkoz FP; Kut E; Katgi N; Sakalar T; Akyol M; Ellez Hİ; Topcu A; Erdoğan AP; Pilanci KN; Hedem E; Arak H; Akdeniz N; Alan Ö; Yapar B; Nart D; Yumuk PF
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):865-875. PubMed ID: 35381885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.
    Mountzios G; Planchard D; Metro G; Tsiouda D; Prelaj A; Lampaki S; Shalata W; Riudavets M; Christopoulos P; Girard N; Albarrán-Artahona V; Garcia Campelo R; Samitas K; Banna GL; Boukovinas I; Agbarya A; Koumarianou A; Perdikouri EI; Kosmidis P; Linardou H; Mauri D; Mavroudis D; Athanasiadis I; Kalofonos H; Xenidis N; Korantzis I; Ardavanis A; Rallis G; Bottiglieri A; Efthymiadis K; Oikonomopoulos G; Kokkalis A; Saloustros E; Tsoukalas N; Bartzi D; Economopoulou P; Psyrri A; Reck M; Lo Russo G
    JTO Clin Res Rep; 2023 Jan; 4(1):100433. PubMed ID: 36793384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies.
    Uy NF; Merkhofer CM; Baik CS
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.
    Kirchner M; Kluck K; Brandt R; Volckmar AL; Penzel R; Kazdal D; Endris V; Neumann O; Seker-Cin H; Goldschmid H; Glade J; Allgäuer M; Kriegsmann M; Winter H; Muley T; Perner S; Frost N; Reck M; Fröhling S; Schirmacher P; Thomas M; Budczies J; Christopoulos P; Stenzinger A
    ESMO Open; 2021 Oct; 6(5):100253. PubMed ID: 34487971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
    Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
    Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.